Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Share-based Compensation (2016 - 2025)

Spero Therapeutics' Share-based Compensation history spans 10 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 33.0% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $4.3 million, down 44.5%, while the annual FY2025 figure was $4.3 million, 44.5% down from the prior year.
  • Share-based Compensation reached $1.0 million in Q4 2025 per SPRO's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.2 million in Q1 2022 to a low of $714000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $1.9 million, with a median of $2.0 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: soared 114.51% in 2021, then plummeted 66.21% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $2.9 million in 2021, then dropped by 14.72% to $2.5 million in 2022, then decreased by 20.02% to $2.0 million in 2023, then fell by 24.74% to $1.5 million in 2024, then tumbled by 33.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Share-based Compensation are $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $714000.0 (Q2 2025).